Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.

Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O.

Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894.

2.

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O.

Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7.

PMID:
28069279
3.

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loët X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J.

Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740. Epub 2009 Jun 23.

4.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
5.

Masitinib for the treatment of canine atopic dermatitis: a pilot study.

Daigle J, Moussy A, Mansfield CD, Hermine O.

Vet Res Commun. 2010 Jan;34(1):51-63. doi: 10.1007/s11259-009-9332-2. Epub 2009 Dec 23.

PMID:
20033487
6.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
7.

[Mastocytosis: revisited with new cytogenetic data].

Vaes M, Vereecken P, de Wind R, Andry G, Li R, Bron D.

Rev Med Brux. 2012 Jan-Feb;33(1):12-21. Review. French.

PMID:
22512145
8.

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.

PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375. Epub 2011 Oct 21.

9.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.

Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.

PMID:
20211560
10.

Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.

Gruson B, Lortholary O, Canioni D, Chandesris O, Lanternier F, Bruneau J, Grosbois B, Livideanu C, Larroche C, Durieu I, Barete S, Sevestre H, Diouf M, Chaby G, Marolleau JP, Dubreuil P, Hermine O, Damaj G.

Br J Haematol. 2013 May;161(3):434-42. doi: 10.1111/bjh.12265. Epub 2013 Feb 22.

PMID:
23432617
11.

[Mastocytosis and anaesthesia].

Dewachter P, Mouton-Faivre C, Cazalaà JB, Carli P, Lortholary O, Hermine O.

Ann Fr Anesth Reanim. 2009 Jan;28(1):61-73. doi: 10.1016/j.annfar.2008.09.022. Epub 2008 Dec 18. Review. French.

PMID:
19097849
12.

Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.

Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, Williams HC.

Health Technol Assess. 2005 Jan;9(1):iii-212.

13.

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.

PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.

14.

Cladribine therapy for systemic mastocytosis.

Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R.

Blood. 2003 Dec 15;102(13):4270-6. Epub 2003 Aug 21.

15.

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.

Pardanani A, Tefferi A.

Curr Opin Hematol. 2010 Mar;17(2):125-32. doi: 10.1097/MOH.0b013e3283366c59. Review.

PMID:
20075725
16.

Most common clinical presentations of cutaneous mastocytosis.

Bulat V, Mihić LL, Situm M, Buljan M, Blajić I, Pusić J.

Acta Clin Croat. 2009 Mar;48(1):59-64. Review.

PMID:
19623875
17.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
19.

Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.

Simon J, Lortholary O, Caillat-Vigneron N, Raphaël M, Martin A, Brière J, Barète S, Hermine O, Casassus P; Group AFIRMM (Association française pour les initiatives de recherche sur le mastocyte et les mastocytoses).

Pathol Biol (Paris). 2004 Jun;52(5):294-9. Review.

PMID:
15217717
20.

Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.

Butterfield JH, Tefferi A, Kozuh GF.

Leuk Res. 2005 Feb;29(2):131-4.

PMID:
15607359

Supplemental Content

Support Center